Ipsen races towards US profitability a year early
This article was originally published in Scrip
A turnaround in Ipsen's US business is underpinning a transformation at the mid-sized French pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins. The company's CEO says it is now on track to reach US profitability one year earlier than forecast.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.